Poseida Therapeutics, Inc.

About Us

Poseida Therapeutics is a clinical-stage biotechnology company translating best-in-class cell therapies and genetic medicines into lifesaving treatments for patients in need. We are developing a pipeline of allogeneic CAR-T product candidates in different cancers and genetic medicines for rare genetic diseases with our industry-leading gene-editing technologies, including our proprietary non-viral piggyBac? DNA Modification System and Cas-CLOVER? Site-specific Gene-Editing System.

Careers at Poseida Visit our site

Our Mission

At Poseida, we are creating the next wave of cell therapies and genetic medicines with the capacity to cure. Every day we are moving closer to transforming the treatment of life-threatening diseases. Our gene engineering technologies represent the next wave of innovation, giving new hope to patients with cancers and genetic disease.

Who we are Our commitment to patients

Our Science

We are developing therapies to revolutionize the treatment of cancers and genetic disease in pursuit of single treatment cures. Our vision is to leverage our best-in-class gene engineering technologies – spanning gene insertion, gene editing, and delivery. This robust set of industry-leading tools lays the foundation for developing a safer, more durable, and more efficient suite of treatments.

Our technology platforms Our pipeline

员工视角

• A Culture of Creativity

  A Culture of Creativity

  作者: Mark Gergen

  I recently rewatched one of my favorite TED Talks that was recorded back in 2006 by the late Sir Ken Robinson, an educator, author and speaker…

  2024年3月5日
• Manufacturing Approach in Cell Therapy as a Strategic Advantage

  Manufacturing Approach in Cell Therapy as a Strategic Advantage

  作者: Loren Wagner

  Selecting and designing a manufacturing approach is not always considered a strategic endeavor for biotech companies, but for those with long-term…

  2024年1月17日
• CAR-T for Oncology and Approaching the Allogeneic Tipping Point

  CAR-T for Oncology and Approaching the Allogeneic Tipping Point

  作者: Mark Gergen

  The road to disruptive innovation is seldom straight and narrow. Defying conventional wisdom and going against the grain, especially in a crowded and…

  2023年12月19日

员工评价

• Christopher Martin

  in vivo immunologist - drug developer - translational

  ““I think this is a unique company in that it not only appreciates daring and creative solutions, but acts upon them.“ ”